Equities research analysts at Oppenheimer Holdings Inc. began coverage on shares of TherapeuticsMD Inc (NASDAQ:TXMD) in a report issued on Tuesday. The firm set an “outperform” rating and a $12.00 price target on the stock. Oppenheimer Holdings Inc.’s price target points to a potential upside of 67.83% from the stock’s current price.

TherapeuticsMD (NASDAQ:TXMD) opened at 7.15 on Tuesday. The stock’s market capitalization is $1.41 billion. The stock’s 50 day moving average is $6.26 and its 200-day moving average is $7.34. TherapeuticsMD has a 12 month low of $4.39 and a 12 month high of $11.26.

Several hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in TherapeuticsMD by 8.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,465,462 shares of the company’s stock worth $159,800,000 after buying an additional 1,798,290 shares in the last quarter. Bamco Inc. NY boosted its stake in shares of TherapeuticsMD by 105.2% in the third quarter. Bamco Inc. NY now owns 461,264 shares of the company’s stock valued at $3,141,000 after buying an additional 236,468 shares in the last quarter. Dai Ichi Life Holdings Inc. acquired a new stake in shares of TherapeuticsMD during the third quarter valued at about $882,000. The Manufacturers Life Insurance Company acquired a new stake in shares of TherapeuticsMD during the third quarter valued at about $710,000. Finally, Rock Springs Capital Management LP boosted its stake in shares of TherapeuticsMD by 14.3% in the third quarter. Rock Springs Capital Management LP now owns 1,800,000 shares of the company’s stock valued at $12,258,000 after buying an additional 225,000 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “TherapeuticsMD Inc (TXMD) Now Covered by Oppenheimer Holdings Inc.” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of international copyright and trademark laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/11/24/therapeuticsmd-inc-txmd-now-covered-by-oppenheimer-holdings-inc.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.